Quick answer: Compounded GLP-1s usually cost less than the brand-name pens, but not always: compounded semaglutide runs $99–$324/mo and compounded tirzepatide $125–$432/mo all-in at the starting dose, versus $149–$499/mo for brand self-pay (Wegovy pill from $149, Zepbound $299–$449, Wegovy pen $349, Mounjaro $499). All checked Oct 20, 2026. The catch: a "$99/month" headline often hides a separate $49–$79 membership fee that raises the real all-in cost to $148–$178. Compounded versions are not FDA-approved and are not the same as the brand-name drugs. Always compare the all-in monthly number, not the headline.
As of Oct 20, 2026: brand prices re-checked on NovoCare and LillyDirect; compounded prices from our ranked cost tables.
- Compounded semaglutide runs $99–$324/mo and compounded tirzepatide $125–$432/mo all-in at the starting dose, across the sellers in our compounded semaglutide cost and compounded tirzepatide cost tables; brand self-pay runs $149–$499/mo. The FDA-approved Wegovy pill ($149 at its starting dose) costs less than 8 of the 15 compounded semaglutide plans.
- Teaser pricing is the biggest trap: many "from $99" offers add a $49–$79/mo membership on top — ask for the total monthly charge before enrolling.
- Compounded GLP-1 medications are not FDA-approved and have not undergone the same regulatory review as Wegovy, Ozempic, Zepbound, or Mounjaro.
- Both paths require a prescription from a licensed clinician; neither is available over the counter.
- Verify any provider by checking that they name their compounding pharmacy and that the pharmacy is state-licensed and verifiable.
Compare published GLP-1 prices →
Compounded vs brand GLP-1 cost at a glance (2026)
| Option | Typical all-in cost / month | FDA-approved? | Requires Rx? |
|---|---|---|---|
| Compounded semaglutide (telehealth) | $99–$324 all-in at the starting dose (15 sellers) | No | Yes |
| Compounded tirzepatide (telehealth) | $125–$432 all-in at the starting dose (13 sellers) | No | Yes |
| Wegovy pen (brand, self-pay) | $349 ($199 for a new patient's first 2 fills; $399 for Wegovy HD 7.2 mg; NovoCare) | Yes | Yes |
| Wegovy pill (brand, self-pay) | $149 at 1.5 mg, $199 at 4 mg, $299 at 9 and 25 mg (NovoCare) | Yes | Yes |
| Zepbound (brand, self-pay vials) | $299 at 2.5 mg, $399 at 5 mg, $449 at 7.5–15 mg (LillyDirect vials or KwikPen) | Yes | Yes |
| Ozempic (brand, self-pay) | $349 at 0.25–1 mg, $499 at 2 mg (NovoCare); off-label for weight | Yes (T2DM) | Yes |
| Mounjaro (brand, self-pay) | $499 at every dose (LillyDirect single-dose pen); off-label for weight | Yes (T2DM) | Yes |
Prices checked Oct 20, 2026 (brand prices on NovoCare and LillyDirect; compounded prices in our cost tables) and change frequently — verify current figures with each manufacturer or provider before making any decision. Compounded semaglutide and tirzepatide are not FDA-approved and are not therapeutically equivalent to the brand-name drugs. See the GLP-1 Telehealth Pricing 2026 dataset for a broader provider comparison.
How the real cost gap works in 2026
For several years, GLP-1 headlines focused on the gap between brand list prices (often $1,000–$1,300/month without insurance) and compounded alternatives at $99–$250. That gap has narrowed significantly. Both Novo Nordisk and Eli Lilly now run direct self-pay programs that bring brand costs down to $149–$499 a month, depending on the drug, form and dose (checked Oct 20, 2026).
That means the honest comparison in 2026 is compounded vs. brand self-pay, not compounded vs. list price. Compounded semaglutide ($99–$324 all-in) still costs less than the Wegovy pen ($349), but the Wegovy pill starts at $149, inside the compounded range. Compounded tirzepatide ($125–$432) overlaps with Zepbound's LillyDirect tiers ($299–$449): the cheapest compounded plans cost less, while 2 of the 13 sellers in our table charge more than Zepbound's $299 starting price. At higher compounded tirzepatide doses, the price gap can be narrow or absent.
The cost comparison also shifts depending on what's included. Some brand programs include wraparound support, pharmacy fulfillment, or nurse-line access; some compounded telehealth providers charge a bare medication price with support billed separately. Always price the full program, not just the vial.
How brand self-pay programs changed the math
Wegovy (semaglutide for weight management). Through NovoCare Pharmacy, Novo Nordisk sells the Wegovy pen for $349 a month at 0.25 to 2.4 mg ($399 for Wegovy HD 7.2 mg), well below the $1,349.02 list price. New patients pay $199 for each of their first 2 fills at 0.25 or 0.5 mg, through Dec 31, 2026. The daily Wegovy pill costs $149 at 1.5 mg, $199 at 4 mg and $299 at 9 and 25 mg. Prices checked Oct 20, 2026; the intro offer is time-limited, so verify current availability directly at the Wegovy NovoCare page before citing it.
Zepbound (tirzepatide for weight management). Eli Lilly's LillyDirect program sells Zepbound vials and KwikPens at $299 a month at 2.5 mg, $399 at 5 mg and $449 at 7.5–15 mg if each refill comes within 45 days (checked Oct 20, 2026), accessed through the LillyDirect platform. The program has specific eligibility and access conditions; confirm those on Lilly's site at the time you're evaluating your options.
Mounjaro and Ozempic are approved for type 2 diabetes. Self-pay, the Mounjaro single-dose pen is $499 a month at every dose through LillyDirect, and Ozempic is $349 a month at 0.25 to 1 mg and $499 at 2 mg through NovoCare (checked Oct 20, 2026). Savings cards vary and may not apply to weight-loss use. Confirm with the manufacturer if this applies to you.
These self-pay programs matter because they are the relevant comparison for most people without insurance coverage — not the sticker price.
The teaser-pricing trap
The biggest pitfall on the compounded side isn't the medication cost — it's undisclosed membership fees. A "$99/month" headline typically refers only to the medication vial. Providers commonly charge a separate platform or membership fee of $49–$79/month, bringing the real all-in cost to $148–$178 or more.
Before enrolling with any compounded GLP-1 provider, ask these questions explicitly:
- What is the total monthly charge, including any membership, subscription, platform, or clinical-consult fee?
- Is the per-dose price the same at all doses (i.e., does going from 0.5 mg to 1 mg semaglutide cost more)?
- Is ongoing prescriber access included, or billed separately?
- Are nutrition or lifestyle support included, or add-ons?
Some providers advertise "$99/month" for semaglutide and $79/month for a platform subscription, resulting in an effective $178/month — comparable to, or higher than, more transparent all-in pricing from other providers.
What "not FDA-approved" actually means
This is the most important factual difference between compounded and brand GLP-1 medications. "Not FDA-approved" is not a technicality — it means the FDA has not reviewed the compounded product for safety, effectiveness, or manufacturing quality.
For brand-name drugs like Wegovy, Ozempic, Zepbound, and Mounjaro, FDA approval required multi-year Phase 3 clinical trials involving thousands of participants, demonstrating specific safety and efficacy outcomes before the drug could be marketed. The STEP trials established the evidence base for semaglutide as a weight-management drug; the SURMOUNT trials did the same for tirzepatide — research on those branded molecules, under those specific formulations, following those manufacturing processes.
Compounded medications do not go through that review process. Per the FDA's compounding guidance, compounding is legal under specific conditions — a valid prescription, a licensed compounding pharmacy, and preparation for an individual patient's needs — but the resulting product is not FDA-approved. The FDA has noted that it has received adverse event reports involving compounded semaglutide and tirzepatide, and it advises patients to be aware of the risks of compounded products from facilities it has not reviewed. See the FDA's postmarket drug safety information for current guidance.
This does not make compounded GLP-1s inherently dangerous — millions of prescriptions have been dispensed by licensed 503A pharmacies under clinician supervision. But it is a real, material difference that every patient should understand before choosing between the two options.
How access and prescribing works for each path
Both require a prescription. GLP-1 medications — compounded or brand — are prescription drugs in the United States. They are not available over the counter. Eligibility is determined by a licensed clinician based on your individual health profile.
Per the National Institute of Diabetes and Digestive and Kidney Diseases, prescription weight-management medications are generally indicated for adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition.
Brand path. Getting a brand-name GLP-1 typically means a clinician sends a prescription to a retail or specialty pharmacy, then navigating insurance prior authorization (often denied for weight management) or enrolling in a manufacturer savings program. Wait times for initial visits and fulfillment vary widely. Insurance coverage for brand GLP-1s used for weight management remains limited; many commercial plans and Medicare historically exclude this indication, though the landscape is evolving.
Compounded telehealth path. A telehealth provider sends a prescription to a licensed compounding pharmacy; the pharmacy prepares and ships the medication directly. Turnaround tends to be faster than the insurance-approval route for brand drugs. The trade-off is that you are taking a product that has not gone through the FDA's review process for the compounded formulation.
Either way, the prescriber should be reviewing your full health intake — not rubber-stamping requests. If a provider skips a meaningful clinical review, that is a red flag regardless of which medication type they offer.
503A vs 503B compounding pharmacies: what you need to know
When you see a compounded GLP-1 advertised, the pharmacy behind it is almost certainly operating under one of two frameworks:
503A (patient-specific compounding). A 503A pharmacy compounds medications for individual patients based on valid prescriptions. It is licensed by the state, not the FDA, and does not produce large batches for general distribution. The overwhelming majority of compounded GLP-1 prescriptions come from 503A pharmacies.
503B (outsourcing facilities). A 503B outsourcing facility produces larger-volume batches and operates under FDA facility oversight — not FDA product approval. 503B is a higher bar for the facility, but it still does not result in an FDA-approved product. Some 503B facilities operate at scale; others may be newer entrants with less track record.
Neither type produces an FDA-approved product. The key verification steps for either:
- The provider names the pharmacy — any legitimate operation will tell you where your medication is compounded.
- You can independently verify the pharmacy's license through your state's board of pharmacy database.
- The pharmacy is not selling directly to consumers without a prescription — that is not legal compounding.
Be skeptical of providers that decline to name their pharmacy or who claim their source is a "certified" or "FDA-approved" compounding facility — no compounded GLP-1 product is FDA-approved.
What to compare: a total-cost checklist
Before enrolling with any compounded GLP-1 provider, nail down the following costs in writing:
- Monthly medication cost at your starting dose and at higher maintenance doses
- Membership or platform fee (monthly or annual — add it to the med cost)
- Initial and ongoing consultation fees (some providers bill per-visit)
- Shipping cost (included, or per-shipment?)
- Dose-adjustment policy — is moving to a higher dose the same price or more?
- Program support included — is nutrition or lifestyle guidance included, or a paid add-on?
- Cancellation and refund terms — what happens if the medication isn't prescribed, or you need to stop?
Once you have the full picture, compare that all-in monthly number — not the headline.
Where compounded options fit on cost
Compounded GLP-1s are usually the lower-sticker option, but pricing structures vary widely. Some providers quote one all-in monthly price that covers the medication (when prescribed), clinician visits, and any nutrition or lifestyle support; others list a low medication price and bill a membership, per-dose surcharge, or consult fee separately. Many also offer a lower monthly rate if you pay for 3 or 6 months up front, so check refund and cancellation terms before you commit.
The useful comparison is the all-in monthly cost at the dose you expect to reach, set against the brand self-pay programs above. Ask each provider to name the state-licensed 503A pharmacy that prepares its medication. Compounded medications are not FDA-approved and are not the same as the brand-name drugs; medication is prescribed only if clinically appropriate after review by a licensed provider. Not everyone qualifies.
See published pricing from licensed providers at joinnouri.com/weight-loss.
Can you use an HSA or FSA for a compounded GLP-1?
Potentially — but with important qualifications. Compounded GLP-1 medications prepared under a lawful prescription from a licensed pharmacy may be eligible for reimbursement through a Health Savings Account (HSA) or Flexible Spending Account (FSA) as a qualified medical expense under IRC §213(d). Reimbursement typically requires a receipt and, in some cases, a letter of medical necessity from your prescribing provider.
However, HSA/FSA rules are plan-specific and interpretation varies. Do not assume your plan covers this cost. Confirm eligibility with your plan administrator and, for tax questions, consult a tax professional. Many telehealth providers do not accept HSA/FSA cards directly; in that case this applies to reimbursement claims only. For a full breakdown, see our guide to using HSA/FSA for GLP-1 medications.
Related cost guides
- GLP-1 Cost 2026: Complete Guide (All Drugs, All Paths)
- Compounded Semaglutide Cost by Provider (Oct 2026)
- Compounded Tirzepatide Cost by Provider (Oct 2026)
- Semaglutide Cost With and Without Insurance
- Tirzepatide Cost Without Insurance
- Wegovy Cost Without Insurance (2026)
- Zepbound Cost Without Insurance (2026)
- Compounded Semaglutide vs. Wegovy: What's the Difference?
- Compounded Tirzepatide vs. Zepbound: What's the Difference?
- Cheapest Way to Get a GLP-1 (Full Cost Comparison)
Frequently asked questions
How much does compounded semaglutide cost per month?
$99 to $324 a month all-in at the starting dose across the 15 telehealth sellers in our price table (checked Oct 20, 2026). Some low headline prices carry a separate monthly membership fee that raises the real total, so always ask for the all-in monthly number. Compounded semaglutide is not FDA-approved and is not the same as Wegovy or Ozempic.
Is compounded semaglutide cheaper than Ozempic?
At the starting dose, yes on sticker price: compounded semaglutide runs $99 to $324 a month all-in across the 15 sellers in our table, vs. $349 a month for Ozempic self-pay at 0.25 to 1 mg ($499 at 2 mg) through NovoCare (checked Oct 20, 2026). But compounded semaglutide is not FDA-approved, and you should compare the all-in price including any membership or platform fee before concluding you're saving money.
Is compounded GLP-1 FDA-approved?
No. Compounded GLP-1 medications — including compounded semaglutide and compounded tirzepatide — are not FDA-approved. The FDA has not reviewed the compounded product for safety, efficacy, or quality. Compounding from a state-licensed 503A pharmacy under a valid prescription is legal, but it is not the same as an FDA-approved drug. Use a provider that names and verifies its pharmacy.
What is the real all-in monthly cost of compounded semaglutide?
Often higher than the headline. A "$99/month" medication price frequently comes with a separate $49–$79 monthly membership or platform fee, making the real cost $148–$178/month or more. Ask any provider: "What is my total monthly charge, all fees included, at each dose?" before enrolling.
What is the difference between 503A and 503B compounding pharmacies?
A 503A pharmacy compounds patient-specific medications under a valid prescription and is licensed by the state. A 503B outsourcing facility produces larger batches under FDA facility oversight — a higher operational bar, but still not FDA drug approval. Neither produces an FDA-approved product. The key verification step for either: the provider names the pharmacy, and you can look it up in the state board of pharmacy database.
Why is compounded tirzepatide cheaper than Zepbound?
Because it doesn't carry the manufacturing, clinical-trial, and regulatory costs of an FDA-approved brand-name drug. It's prepared by a compounding pharmacy under a patient-specific prescription. Compounded tirzepatide runs $125 to $432 a month all-in at the starting dose across the 13 sellers in our table, versus Zepbound's LillyDirect self-pay tiers of $299 to $449 a month by dose (checked Oct 20, 2026); 2 of those sellers charge more than Zepbound's $299 starting price. Prices change — verify current figures directly. Compounded tirzepatide is not FDA-approved and is not the same as Zepbound.
The bottom line
Compounded GLP-1s usually cost less than the brand-name pens on sticker, but not always: the Wegovy pill starts at $149 a month, inside the compounded semaglutide range, and 2 compounded tirzepatide sellers in our table charge more than Zepbound's $299 starting price. But the real test is the all-in monthly cost. Membership fees, per-dose surcharges, and support add-ons can make a "$99/month" headline into a $178/month reality. Read the fine print.
The non-negotiable factual difference: compounded GLP-1 medications are not FDA-approved and are not therapeutically equivalent to the brand-name drugs. That distinction matters for your decision. Both paths require a legitimate prescription from a licensed clinician, and both work best with a clinical program behind them — not just a vial.
If you'd like to explore whether a compounded GLP-1 program is appropriate for you: see what licensed providers charge.
Sources and references
- FDA: Human Drug Compounding — Questions and Answers (U.S. Food & Drug Administration)
- FDA: Postmarket Drug Safety Information for Patients and Providers (U.S. Food & Drug Administration)
- Prescription Medications to Treat Overweight & Obesity (National Institute of Diabetes and Digestive and Kidney Diseases, NIH)
- CMS: $50/month Access to GLP-1 Medications for Medicare Beneficiaries (Centers for Medicare & Medicaid Services)
- Wegovy Self-Pay & Savings — NovoCare (Novo Nordisk; verify current pricing before citing)
- Zepbound Self-Pay Vials — LillyDirect (Eli Lilly; verify current pricing and program terms before citing)
- GLP-1 Drugs: Cost and Savings Guide (GoodRx, for market pricing context; verify figures at time of use)
- GLP-1 Telehealth Pricing 2026 Dataset (Nouri; provider pricing data, last updated 2026-10-14)
Medically reviewed by Amber Patel, MD. Nouri content is reviewed by licensed clinicians and updated as pricing and regulations change.
Medical disclaimer: This article is general educational information about medication cost and access, not medical advice. GLP-1 medications are prescription drugs; eligibility is determined by a licensed clinician based on your individual health. Not everyone qualifies for treatment. Compounded semaglutide and compounded tirzepatide are not FDA-approved drugs and are not the same as, or therapeutically equivalent to, Wegovy®, Ozempic®, Zepbound®, or Mounjaro®. The FDA has not verified the safety, efficacy, or quality of compounded GLP-1 preparations. Compounding from a state-licensed 503A pharmacy with a valid prescription is legal, but the product is not FDA-approved.
Safety information: GLP-1 medications carry a boxed warning for thyroid C-cell tumors. Do not use if you or a family member has a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Stop use and contact your provider if you experience symptoms of a serious allergic reaction, pancreatitis, or gallbladder problems; these medications are not for use during pregnancy. Common side effects include nausea, diarrhea, vomiting, constipation, and abdominal pain. Talk to your provider about all risks before starting treatment.
Pricing disclaimer: All prices were checked Oct 20, 2026 and change frequently. Verify current figures with each manufacturer, your pharmacy, and your insurer on the day you make a decision. Brand pricing from manufacturer self-pay or savings programs is subject to eligibility and program terms.
FSA/HSA disclaimer: HSA/FSA reimbursement eligibility for compounded GLP-1 medications varies by plan. This is not tax or financial advice. Confirm eligibility with your plan administrator and consult a qualified tax professional.
Ozempic® and Wegovy® are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Nouri is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Nouri is an independent publisher: it does not prescribe, review patient assessments, or sell medication. Talk to a licensed clinician before starting or changing any medication or treatment.
Compare licensed GLP-1 providers
Published cash prices side by side, with the month we checked them and a link to each provider's own site. Nouri doesn't prescribe or sell medication.